Error message

The imagesloaded library was not found! Please following the instructions from the README.txt to get the plugin.

Natural Breast Cancer Treatment

Read more to learn about these topics


Breast Cancer Statistics. On average, 72 Canadian women and 904 American women will be diagnosed with breast cancer every day. In Canada and the U.S., breast cancer is the most common cancer in women (not considering non-melanoma skin cancers) (Canadian Cancer Society 2017, National Cancer Institute 2018). Because of early detection of disease, and improved therapies, less woman are dying of breast cancer. However, breast cancer is still the 2nd leading cause of death from women with cancer (Canadian Cancer Society 2017).


Alternative Medicine and Natural Treatment for Breast Cancer,

Complementary and alternative medicine is used by 48%-70% of breast cancer survivors in the US (Nahleh and Tabbara 2003). Are these therapies effective? Some studies say they aren’t and are actually detrimental (Johnson, et al 2018), while other studies show significant benefit from breast cancer patients using natural medicines (Standish 2013). What is the difference between these studies? The first study included any “unproven therapies from a nonmedical provider,” as Dr. Johnson said to treat breast cancer and the second study showing benefit, the BIORC study, is a human study in which stage 4 breast cancer patients received protocols by naturopathic oncologists. It is very important for breast cancer patients to receive expert guidance from an experienced naturopathic doctor with years of experience treating cancer patients and advanced naturopathic tools such as OncoTherm hyperthermia to effectively treat advanced cancers. Treating cancer by searching on the internet and treating cancer yourself is not a strategy that should be followed. The stakes are far too high. Our clinic treats all cancers and services patients from all over North America. Our success is based on individualizing cancer treatment. Every cancer is treated uniquely & every patient is treated individually. Let’s look at some outcomes from human studies using natural medicines and then we will look at cases treated at our clinic using our protocols.


Human study showing natural alternatives to chemo superior to chemotherapy in stage 4 breast cancer.

The BIORC naturopathic breast cancer study showed that the 5 year survival rate for these breast cancer patients was 77.5% vs. 24% survival from SEER data collected from patient outcomes using surgery, chemotherapy, radiation and hormone therapy. This is a significant improvement in survival from these natural treatments for breast cancer, which included naturopathic IV therapies, mistletoe and supplements. This protocol, with variations where needed, are used at our clinic. The IV therapies formed an integral part of the protocol and it was found that 100% of the stage 4 breast cancer patients were alive 3 years following therapy, while 70% of patients who did not undergo the naturopathic IV protocol were alive at 3 years (Standish 2013). The results of this Bastyr University study showed a median survival time of 43 months with the use of the naturopathic cancer therapies versus chemotherapy survival times of 33, 12.3 and 9 months.

Let’s take a look at a stage 4 breast cancer patient treated at our clinic using these protocols along with individualized naturopathic therapies.


Stage 4 breast cancer in remission without use of chemotherapy.

This patient is a 66 year old female diagnosed with stage 4, ER/PR+, HER2- advanced breast cancer who had already undergone a full mastectomy when I had first consulted with her. She had bone metastasis to her lumbar and thoracic spine, as well as her ileum, left hip and rib. She was very leery of undergoing chemotherapy treatments. However, we worked with her oncologist to use non-chemotherapy options along with our naturopathic therapies and she was given letrozole, an aromatase inhibitor, along with our naturopathic IV therapies, mistletoe injections, OncoTherm hyperthermia treatments as well as supplements and diet. She was followed using CT scans, tumor markers and circulating tumour cell testing.  She tolerated treatment very well, remained fit and active, did not lose any hair and her blood counts remained normal throughout therapy. She suffered no fatigue, or nausea. After 5 months of therapy a repeat CT showed no evidence of disease, lab tests showed tumor markers for breast cancer were within normal limits and circulating tumor cell count was at 0. She has been declared in remission.

First bone scan showing metastasis (movement of cancer) to the bones before treatment:

CT scan after naturopathic treatment and letrozole showing no active cancer:

Circulating tumour cell (CTC) and tumour marker testing showing normal levels following treatment. These blood tests are used to show how advanced breast cancer patients respond to treatment. All of her tumour markers are within range and her CTC count is 0 showing no movement of breast cancer cells.

There is no active detectable cancer following treatment and she is now considered to be in remission from stage 4 breast cancer. This was accomplished with the use of naturopathic IV therapies, mistletoe injections, OncoTherm hyperthermia treatments as well as specific supplementation and diet, all given at our clinic along with an aromatase inhibitor.  This patient continues to be very active with yoga classes and daily walks. Her energy remains at 9/10, as it did throughout her treatments. The best news is that she will be able to enjoy time with her first grandchild!

These naturopathic therapies are available to patients without referral. Please call our front desk at 1-204-775-4539 if you wish to become a patient and receive our advanced naturopathic oncology treatments.


Is this a natural cure for breast cancer?

No. A breast cancer patient is said to be in remission if there is no detectable cancer present. If a patient remains in remission for 5 years it may be said that they are “cured”, however, there is no single “cure” for cancer.


How Cancer Forms.

In order for any cancer to arise, tissues must undergo three phases of cellular changes, called initiation, promotion and progression. Initiation entails irreversible structural changes to DNA through substances foreign to our body (Rous and Kidd 1941, Mackenzie and Rous 1941). Promotion, on the other hand, means that once an initiator has changed the conformation of the DNA, the cells with these changes are now susceptible to the action of promoters. Up until this point, the DNA changes were passed onto daughter cells but the cell line did not display any abnormal behaviour (Rous and Kidd 1941, Mackenzie and Rous 1941). However, once a promotor causes a genetic mutation, the cell begins to exhibit the characteristics of cancer (see our What is Cancer? page for more information). Typically, our body will sense such abnormal activity and stop the progression of these cells to cancer (Rous and Kidd 1941, Mackenzie and Rous 1941). However, in the last phase of progression, the cell line accumulates more mutations that allow for a tumour to form despite our body’s defences.


How Can We Prevent Breast Cancer?

Toxins cause cancer by modifying DNA irreversibly in the initiation and promotion phases. These DNA changes lead to the proliferation of cells, recruitment of inflammatory cells, more reactive oxygen species that damage DNA, as well as less DNA repair (Coussens and Werb 2002). As such, enhancing the body’s ability to detoxify metals and chemicals transmitted from the environment using chelation, for example, may help prevent or reduce such changes to DNA and cells.


Chemo can cause aggressive cancer progression after treatment.

As of 2000, the NIH recommends that patients with breast cancer, after primary treatment with mastectomy or lumpectomy, be given adjuvant chemotherapy (NIH 2000). These chemotherapies include: paclitaxel, docetaxel, doxorubicin, epirubicin, cyclophosphamide, or flourouracil (5-FU). However, these chemotherapy agents cause aggressive return of cancer following treatment (Chrisanthar et al. 2008, Hansen et al. 2015, Smith et al. 2006, Takahashi et al. 2013, Végran et al. 2006). Although many mechanisms are implicated in the formation of resistance, resistance mutations typically arise early on in breast stem cells (Dean et al. 2010, Lynch et al. 2006, Yagüe et al. 2007).

As well, the chemo-agent called paclitaxel is a first-line form of conventional treatment for breast cancer (Valvero and Hortobagyi 2003). However, tumours may become resistant to paclitaxel through NF-κB activation and as such, this drug is no longer able to treat advanced stages of breast cancers (Pianetti et al. 2001). Chemotherapy can be a powerful tumour inhibitor but it can cause a deadly backlash of the cancer after treatment that can lead to a more aggressive cancer with metastasis or spread later on (Aldonza, et al. 2017).


Holistic breast cancer treatment to deal with the side-effects of chemotherapy.

Although chemotherapy is a life-saving form of treatment, these drugs often have many side effects. A common side effect includes neurotoxicity, leading to peripheral neuropathy, which can be reduced using IV ALA (Gedlicka et al. 2002 and 2003; Melli et al. 2008). Furthermore, up to 50-80% of patients treated with chemotherapy will experience diarrhea (Stein et al. 2010). As such, using ALA prior to chemo-agents like methotrexate helps protect against intestinal toxicity and improve the consistency of stool (Dadhania et al. 2010). IV ALA also helps with cardiotoxicity (Al-Majed et al. 2002, Balachandar et al. 2003) and kidney damage (Malarkodi et al. 2003a, b, c, d; Murugavel and Pari 2004).


Cancer Treatments at Our Centre  (International and local patients). Contact our cancer clinic.

All of these naturopathic oncology treatments are available at the Centre For Natural Pain Solutions in Winnipeg, Canada. Out-of-town patients travel to Winnipeg and stay for a length of time in order to receive daily treatments at our centre. Please call our office for an appointment or to receive more information at 1-204-775-4539 or contact us via email using the contact form. We hope to see you at our centre!

References

Aggarwal, B. B., Shishodia, S., Takada, Y., et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-kappa B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11: 7490–8.

Al-Majed, A. A., Gdo, A. M., Al-Shabanah, O. A., et al. (2002) Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res. 46(6):499–503.

Aldonza, Mark Borris Docdoc et al. “Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.” Experimental & molecular medicine (2017).

Balachandar, A. V., Malarkodi, K. P., and Varalakshmi, P. (2003) Protective role of DLalpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol. 22(5):249–54.

“Canadian Cancer Society” and “National Cancer Institute of Canada Canadian Cancer Statistics.” (2017) Retrieved from:  http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/ ?region=bc

Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature. 420(6917):860–7.

Chrisanthar, R., Knappskog, S., Løkkevik, E., et al. (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 3(8):e3062.

Dadhania, V. P., Tripathi, D. N., Vikram, A., et al. (2010) Intervention of alpha-lipoic acid ameliorates methotrexate-induced oxidative stress and genotoxicity: A study in rat intestine. Chem Biol Interact. 183(1):85–97.

Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–84.

Duarte, V. M., Han, E., Veena, M. S., et al. (2010) Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKK beta protein of the NF kappa B pathway. Mol Cancer Ther. 9:2665–75.

Fetoni, A. R., Paciello, F., Mezzogori, D., et al. (2015) Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer. 113(10):1434–44.

Hansen, S. N., Westergaard, D., Thomsen, M. B., et al. (2015) Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumour Biol. 36(6):4327–38.

Gedlicka, C., Scheithauer, W., Schull, B., a et al. (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol. 20:3359–61.

Gedlicka, C., Kornek, G. V., Schmid, K., et al. (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol. 14:339–40.

Lynch, M. D., Cariati, M., and Purushotham, A. D. (2006) Breast cancer, stem cells and prospects for therapy. Breast Cancer Res. 8:211.

Mackenzie, I. and Rous, P. (1941) The experimental disclosure of latent neoplastic changes in tarred skin. J Exp Med. 73(3):391–416.

Malarkodi, K. P., Balanchandar, A. V., and Varlakshmi. P. (2003a) The influence of lipoic acid on adriamycin induced nephrotoxicity in rats. Mol Cell Biochem. 247:15–22.

Malarkodi, K. P., Balanchandar, A. V., and Varlakshmi. P. (2003b) The influence of lipoic acid on adriamycin-induced hyper-lipidemic nephrotoxicity in rats. Mol Cell Biochem. 247:139–45.

Malarkodi, K. P., Balanchandar, A. V., and Varlakshmi. P. (2003c) Protective effect of lipoic acid on adriamycin-induced lipid peroxidation in rat kidney. Mol Cell Biochem. 247:9–13.

Malarkodi, K. P., Balanchandar, A. V., Sivaprasad, R., et al. (2003d) Prophylactic effect of lipoic acid against adriamycin-induced peroxidative damages in rat kidney. Ren Fail. 25:367–77.

Melli, G., Taiana, M., Camozzi, F., et al. (2008) Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 214(2):276–84. Morré, D. J. and Gilmartin, D. S. (2015) Estimation of the Accuracy of the ONCOblot® Tissue of Origin Cancer Test. West Lafayette, IN: MorNuCo.

Murugavel, P. and Pari, L. (2004) Attenuation of chloroquine-induced renal damage by alpha-lipoic acid: possible antioxidant mechanism. Ren Fail. 26(5):517–24. National Cancer Institute. (2018) Retrieved from: https://www.cancer.gov/types/common-cancers

National Institutes of Health. (2000) Adjuvant Therapy for Breast Cancer, Consensus Development Conference Statement. November 1-3, 2000. Retrieved from:  https://consensus.nih.gov/2000/ 2000AdjuvantTherapyBreastCancer114html.htm

Nahleh Z. Tabbara IA. Complementary and alternative medicine in breast cancer patients. Palliat Support Care. 2003;1:267–273. [PubMed]

Pianetti, S., Arsura, M., Romieu-Mourez, R., et al. (2001) Her-2/neu overexpression induces NF-kappa B via a PI3-kinase/Akt pathway involving calpain-mediated degradation of I kappa-B-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene. 20: 1287–99.

Rous, P. and Kidd, J. G. (1941) Conditional neoplasms and subthreshold neoplastic states: A study of the tar tumors of rabbits. J Exp Med. 73(3):365–90.

Shakibaei, M., Kraehe, P., Popper, B., et al. (2015) Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. Bmc Cancer. 15:250.

Shehzad, A., Lee, J., and Lee, Y. S. (2013) Curcumin in various cancers. Biofactors. 39(1):56–68.

Smith, L., Watson, M. B., O’Kane, S. L., et al. (2006) The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 5(8):2115–20.

Standish, LJ. Does Integrative Oncology Improve Survival in Advanced Cancer Patients? Report from the Bastyr Integrative Oncology Research Center (BIORC). 10th International Conference of the Society for Integrative Oncology (ME8659). The Society for Integrative Oncology. October 20-22, 2013, Vancouver, BC.

Stein, A., Voigt, W., and Jordan, K. (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2(1):51–63.

Takahashi, K., Tanaka, M., Inagaki, A., et al. (2013) Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. Int J Oncol. 43(6):1985-91.

Thangapazham, R. L., Sharma, A., and Maheshwari, R. K. (2006) Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 8(3):E443–9.

Valero, V. and Hortobagyi, G. N. (2003) Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 21:959–62.

Végran, F., Boidot, R., Oudin, C., et al. (2006) Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res. 12:5794–800.

Yagüe, E., Arance, A., Kubitza, L., et al. (2007) Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 67:1130–7.

Condition Taxonomy: